Revolution Medicines presented additional details from its Phase 3 pancreatic cancer study featuring daraxonrasib at ASCO, with investigators describing results as “landscape-changing.” In the study, daraxonrasib nearly doubled survival compared with standard chemotherapy for patients with RAS G12–driven disease, with the survival benefit extending broadly across the all-comer population as a secondary endpoint. At ASCO, Revolution reported that daraxonrasib extended median survival to 13.2 months across all recipients versus 6.6 months with chemotherapy. For patients with KRAS mutation subgroups aligned to the trial’s RAS G12 focus, the median survival benefit and disease control measures were similarly pronounced. Clinicians quoted in the report emphasized the magnitude of survival for second-line metastatic pancreatic cancer and the rapid improvements noted in patient-reported pain and tumor markers after starting therapy.